AVTE vs. IMRX

In the year-to-date period, AVTE achieves a -2.08% return, which is significantly higher than IMRX's -13.18% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Aerovate Therapeutics, Inc. (AVTE) and Immuneering Corporation (IMRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current AVTE Sharpe Ratio is -0.73, which is lower than the IMRX Sharpe Ratio of -0.50. The chart below compares the historical Sharpe Ratios of AVTE and IMRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither AVTE nor IMRX has paid dividends to shareholders.

The maximum AVTE drawdown since its inception was -95.41%, roughly equal to the maximum IMRX drawdown of -96.86%. Use the drawdown chart below to compare losses from any high point for AVTE and IMRX. For additional features, visit the drawdowns tool.

The current volatility for Aerovate Therapeutics, Inc. (AVTE) is 10.68%, while Immuneering Corporation (IMRX) has a volatility of 21.79%. This indicates that AVTE experiences smaller price fluctuations and is considered to be less risky than IMRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Aerovate Therapeutics, Inc. and Immuneering Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.